Marta Lewandowska

Marta Lewandowska has been in the biotechnology industry since 2010. marta began their career as an Associate Scientist at f-star Biotechnologische Forschung, where they developed new protein-based therapeutics through expression, purification, and characterization. marta was also responsible for sub-cloning antibody fragments from display systems, High Throughput Screening, Yeast Display, Recombinant protein expression, and Molecular biology. In 2013, they joined Biosceptre International as a Scientist, where they were the project leader for monoclonal and polyclonal production, screened therapeutic antibodies for target binding in cell assays and flow cytometry, and developed ELISA, Octet, and cell-based biological functional assay and FACS cell binding assay. In 2015, they joined Crescendo Biologics Ltd as a Senior Scientist II & Project Manager, where they were responsible for project management, differential biology, lead protein and display scientist for the company's first immuno-oncology program, and optimization of the yeast display platform. In 2020, they joined IONTAS as a Team Leader, and in 2021 they became a Program Lead at Mestag Therapeutics.

Marta Lewandowska attended Akademia Bydgoska im. Kazimierza Wielkiego from 2001 to 2006, where they obtained their Master's degree in Biology. In 2010, they attended BD Bioscience for a FACS Aria operator course. In 2011, they attended The Open University for a course in Molecular Biology.